Palvella Therapeutics, Inc. (PVLA) stock analysis
In our weekly check, Palvella Therapeutics, Inc. is graded D (A to F). Of 20 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 11.
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PVLA.
What our checks show for PVLA
Red flags
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The gross margin fell by 92.5 points, to 0%: costs are rising faster than prices.
- Weak EPS forecast
- Analysts expect the net margin to shrink by 88.8 points from today's 0%.
- Earnings per share fell 42.9% a year over the last 3 years.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 81.1% annual volatility. Expect large ups and downs.
- The share count grew by 787% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Thinly traded (about 237 thousand shares a day): buying and selling can move the price.
Strengths
- Debt is low: 0x equity.
- Margins rising
- After its deepest fall the stock recovered in about 3 months.
- Beta -0.17: the stock usually moves less than the market.
Similar companies
LKFT · IMNM · CLDX · MRVI · ALMR · PHVS
Questions
What grade does Palvella Therapeutics, Inc. (PVLA) have?
In our weekly check, Palvella Therapeutics, Inc. is graded D (A to F). Of 20 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 11. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of PVLA stock?
This week's biggest flags for Palvella Therapeutics, Inc.: Weak interest cover, Gross margin falling, Weak EPS forecast. In total 13 of 20 checks show a warning or a red flag.
What does Palvella Therapeutics, Inc. do?
Palvella Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PVLA.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis